Generalized Anxiety Disorder Market Report and Forecast 2025-2034
Description
The generalized anxiety disorder market size in the 7 major markets was valued at USD 1717.50 Million in 2024, driven by the increasing advancements in psychotherapeutic as well as pharmacological treatment options for patients. The market is expected to grow at a CAGR of 5.40% during the forecast period of 2025-2034, with the values likely to reach USD 2906.05 Million by 2034.
Generalized Anxiety Disorder: Introduction
Generalized anxiety disorder (GAD) is marked by persistent feelings of tension and worry that do not seem to go away. Common symptoms include trembling, twitching, trouble falling or staying asleep, sweating, tense muscles, nausea, and trouble breathing, among others. Medicines, counselling, lifestyle changes, and relaxation techniques are some of the common methods used to treat GAD. It may also worsen or instigate other physical conditions, such as insomnia, irritable bowel syndrome, headaches, and migraines.
Generalized Anxiety Disorder Market Analysis
The generalized anxiety disorder market demand is driven by the modern fast paced lifestyles that induce high stress levels in the people. With rising incidence of the condition, there has been heightened awareness and education about addressing mental health issues with proper care. Rapid advancements have been made in diagnostic and screening methods to offer proper treatment to patients.
Conventionally, pharmacological treatment alternatives like duloxetine, escitalopram, pregabalin, quetiapine, and venlafaxine have been used in the market. However, with rising technological advancements in drug development, researchers have developed a non-sedating drug treatment for GAD. BNC210 is a newly developed drug that reduces anxiety by working on cholinergic, a different chemical system in the brain essential in forming memories and signalling uncertainty.
In April 2023, Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. collaborated to initiate a phase II and III clinical study for Ulotaront, a potential treatment for generalized anxiety disorder (GAD). The rising drug developments using a diverse set of approaches to cater to a wider audience are also expected to impact the generalized anxiety disorder market value positively in the forecast period.
Apart from pharmaceuticals, psychological interventions like cognitive behavioural therapy are commonly used to manage GAD.
Generalized Anxiety Disorder Market Segmentation
“Generalized Anxiety Disorder Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapeutic Type
North America holds a significant generalized anxiety disorder market share. Since the population has high awareness of mental health issues, they are more familiar and comfortable with the treatment and management of the disease. The presence of influential pharmaceutical companies keeps working on new drug formulations for patient welfare.
With a well-equipped medical infrastructure, Europe is another major market for GAD. With higher research and academic institutions, the number of product launches and clinical trials occurring in the region is higher. Regulatory frameworks, like the European Medicine Agency, also play a pivotal role in maintaining the efficacy of drug therapies.
The Asia Pacific region is witnessing expediated generalized anxiety disorder market growth due to declining stigmas associated with mental health issues. With increasing urbanisation and changing lifestyles, stress related issues have grown in the people residing in the region. With a vision to address such issues properly, several private and government institutions have partnered to impart education on the same.
Generalized Anxiety Disorder Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Generalized Anxiety Disorder: Introduction
Generalized anxiety disorder (GAD) is marked by persistent feelings of tension and worry that do not seem to go away. Common symptoms include trembling, twitching, trouble falling or staying asleep, sweating, tense muscles, nausea, and trouble breathing, among others. Medicines, counselling, lifestyle changes, and relaxation techniques are some of the common methods used to treat GAD. It may also worsen or instigate other physical conditions, such as insomnia, irritable bowel syndrome, headaches, and migraines.
Generalized Anxiety Disorder Market Analysis
The generalized anxiety disorder market demand is driven by the modern fast paced lifestyles that induce high stress levels in the people. With rising incidence of the condition, there has been heightened awareness and education about addressing mental health issues with proper care. Rapid advancements have been made in diagnostic and screening methods to offer proper treatment to patients.
Conventionally, pharmacological treatment alternatives like duloxetine, escitalopram, pregabalin, quetiapine, and venlafaxine have been used in the market. However, with rising technological advancements in drug development, researchers have developed a non-sedating drug treatment for GAD. BNC210 is a newly developed drug that reduces anxiety by working on cholinergic, a different chemical system in the brain essential in forming memories and signalling uncertainty.
In April 2023, Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. collaborated to initiate a phase II and III clinical study for Ulotaront, a potential treatment for generalized anxiety disorder (GAD). The rising drug developments using a diverse set of approaches to cater to a wider audience are also expected to impact the generalized anxiety disorder market value positively in the forecast period.
Apart from pharmaceuticals, psychological interventions like cognitive behavioural therapy are commonly used to manage GAD.
Generalized Anxiety Disorder Market Segmentation
“Generalized Anxiety Disorder Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapeutic Type
- Antidepressant
- Buspirone
- Benzodiazepines
- Interpersonal Therapy
- Behavior Therapy
- Cognitive Behavioral Therapy
- Mindfulness Based Cognitive Therapy
- Deep Brain Stimulation
- Electroconvulsive Therapy
- Transcranial Magnetic
- Stimulation Vagus Nerve
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
North America holds a significant generalized anxiety disorder market share. Since the population has high awareness of mental health issues, they are more familiar and comfortable with the treatment and management of the disease. The presence of influential pharmaceutical companies keeps working on new drug formulations for patient welfare.
With a well-equipped medical infrastructure, Europe is another major market for GAD. With higher research and academic institutions, the number of product launches and clinical trials occurring in the region is higher. Regulatory frameworks, like the European Medicine Agency, also play a pivotal role in maintaining the efficacy of drug therapies.
The Asia Pacific region is witnessing expediated generalized anxiety disorder market growth due to declining stigmas associated with mental health issues. With increasing urbanisation and changing lifestyles, stress related issues have grown in the people residing in the region. With a vision to address such issues properly, several private and government institutions have partnered to impart education on the same.
Generalized Anxiety Disorder Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Eli Lilly and Company
- GlaxoSmithKline Pharmaceuticals Limited
- Pfizer, Inc.
- Abbott Laboratories
- Bristol-Myers Squibb
- Actavis Pharmaceutical Company
- F. Hoffmann-La Roche
- Sumitomo Dainippon Pharma
- MindMed
- VistaGen Therapeutics, Inc
- Mitsubishi Chemical Group Corporation
- Sanofi
- Mitsubishi Chemical Group Corporation
- Forest Laboratories, Inc
- H. Lundbeck A/S
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Generalized Anxiety Disorder Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Generalized Anxiety Disorder Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Generalized Anxiety Disorder Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Generalized Anxiety Disorder Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Generalized Anxiety Disorder Epidemiology Forecast (2018-2034)
- 5.3.2 France Generalized Anxiety Disorder Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Generalized Anxiety Disorder Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Generalized Anxiety Disorder Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Generalized Anxiety Disorder Epidemiology Forecast (2018-2034)
- 5.4 Japan Generalized Anxiety Disorder Epidemiology Forecast (2018-2034)
- 6 Generalized Anxiety Disorder Market Overview – 7MM
- 6.1 Generalized Anxiety Disorder Market Historical Value (2018-2024)
- 6.2 Generalized Anxiety Disorder Market Forecast Value (2025-2034)
- 7 Generalized Anxiety Disorder Market Landscape – 7MM
- 7.1 Generalized Anxiety Disorder: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Generalized Anxiety Disorder Product Landscape
- 7.2.1 Analysis by Treatment Type
- 7.2.2 Analysis by Route of Administration
- 7.2.3 Analysis by Treatment Type
- 8 Generalized Anxiety Disorder Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Generalized Anxiety Disorder Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Generalized Anxiety Disorder Market Segmentation – 7MM
- 11.1 Generalized Anxiety Disorder Market by Therapeutic Type
- 11.1.1 Market Overview
- 11.1.2 Antidepressant
- 11.1.3 Buspirone
- 11.1.4 Benzodiazepines
- 11.2 Generalized Anxiety Disorder Market by Therapy Type
- 11.2.1 Market Overview
- 11.2.2 Interpersonal Therapy
- 11.2.3 Behavior Therapy
- 11.2.4 Cognitive Behavioral Therapy
- 11.2.5 Mindfulness Based Cognitive Therapy
- 11.3 Generalized Anxiety Disorder Market by Diagnosis
- 11.3.1 Market Overview
- 11.3.2 Deep Brain Stimulation
- 11.3.3 Electroconvulsive Therapy
- 11.3.4 Transcranial Magnetic
- 11.3.5 Stimulation Vagus Nerve
- 11.4 Generalized Anxiety Disorder Market by Region
- 11.4.1 Market Overview
- 11.4.2 United States
- 11.4.3 EU-4 and the United Kingdom
- 11.4.3.1 Germany
- 11.4.3.2 France
- 11.4.3.3 Italy
- 11.4.3.4 Spain
- 11.4.3.5 United Kingdom
- 11.4.4 Japan
- 12 United States Generalized Anxiety Disorder Market
- 12.1 Generalized Anxiety Disorder Market Historical Value (2018-2024)
- 12.2 Generalized Anxiety Disorder Market Forecast Value (2025-2034)
- 12.3 Generalized Anxiety Disorder Market by Disease Type
- 12.4 Generalized Anxiety Disorder Market by Treatment Type
- 13 EU-4 and United Kingdom Generalized Anxiety Disorder Market
- 13.1 Generalized Anxiety Disorder Market Historical Value (2018-2024)
- 13.2 Generalized Anxiety Disorder Market Forecast Value (2025-2034)
- 13.3 Germany Generalized Anxiety Disorder Market Overview
- 13.3.1 Generalized Anxiety Disorder Market by Disease Type
- 13.3.2 Generalized Anxiety Disorder Market by Treatment Type
- 13.4 France Generalized Anxiety Disorder Market Overview
- 13.4.1 Generalized Anxiety Disorder Market by Disease Type
- 13.4.2 Generalized Anxiety Disorder Market by Treatment Type
- 13.5 Italy Generalized Anxiety Disorder Market Overview
- 13.5.1 Generalized Anxiety Disorder Market by Disease Type
- 13.5.2 Generalized Anxiety Disorder Market by Treatment Type
- 13.6 Spain Generalized Anxiety Disorder Market Overview
- 13.6.1 Generalized Anxiety Disorder Market by Disease Type
- 13.6.2 Generalized Anxiety Disorder Market by Treatment Type
- 13.7 United Kingdom Generalized Anxiety Disorder Market Overview
- 13.7.1 Generalized Anxiety Disorder Market by Disease Type
- 13.7.2 Generalized Anxiety Disorder Market by Treatment Type
- 14 Japan Generalized Anxiety Disorder Market
- 14.1 Generalized Anxiety Disorder Market Historical Value (2018-2024)
- 14.2 Generalized Anxiety Disorder Market Forecast Value (2025-2034)
- 14.2.1 Generalized Anxiety Disorder Market by Disease Type
- 14.2.2 Generalized Anxiety Disorder Market by Treatment Type
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 Eli Lilly and Company
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisition
- 20.1.5 Certifications
- 20.2 GlaxoSmithKline Pharmaceuticals Limited
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisition
- 20.2.5 Certifications
- 20.3 Pfizer, Inc.
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisition
- 20.3.5 Certifications
- 20.4 Abbott Laboratories
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisition
- 20.4.5 Certifications
- 20.5 Bristol-Myers Squibb
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisition
- 20.5.5 Certifications
- 20.6 Actavis Pharmaceutical Company
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisition
- 20.6.5 Certifications
- 20.7 F. Hoffmann-La Roche
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisition
- 20.7.5 Certifications
- 20.8 Sumitomo Dainippon Pharma
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisition
- 20.8.5 Certifications
- 20.9 MindMed
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisition
- 20.9.5 Certifications
- 20.10 VistaGen Therapeutics, Inc
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisition
- 20.10.5 Certifications
- 20.11 Mitsubishi Chemical Group Corporation
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisition
- 20.11.5 Certifications
- 20.12 Sanofi
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisition
- 20.12.5 Certifications
- 20.13 Mitsubishi Chemical Group Corporation
- 20.13.1 Financial Analysis
- 20.13.2 Product Portfolio
- 20.13.3 Demographic Reach and Achievements
- 20.13.4 Mergers and Acquisition
- 20.13.5 Certifications
- 20.14 Forest Laboratories, Inc
- 20.14.1 Financial Analysis
- 20.14.2 Product Portfolio
- 20.14.3 Demographic Reach and Achievements
- 20.14.4 Mergers and Acquisition
- 20.14.5 Certifications
- 20.15 H. Lundbeck A/S
- 20.15.1 Financial Analysis
- 20.15.2 Product Portfolio
- 20.15.3 Demographic Reach and Achievements
- 20.15.4 Mergers and Acquisition
- 20.15.5 Certifications
- 21 Generalized Anxiety Disorder Market - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
